Hope for metastatic prostate cancer patients: targeted alpha therapy shows impressive results

​

Nearly three years of research have brought about remarkable results for the majority of 80 patients subjected to targeted alpha therapy of metastatic prostate cancer. The first assessments – describing a full response in two patients in critical clinical condition with extensive metastases – are published in the December issue of the Journal of Nuclear Medicine (JNM), which has displayed images depicting the improvements on its cover page.

Targeted alpha therapy (TAT) of prostate cancer has been developed through joint efforts of the University Hospital Heidelberg, the German Cancer Research Center (DKFZ) and the JRC. The paper is co-authored by the three institutions and the RWTH University Hospital Aachen.

Insights from a three-year research

So far, a total of 80 patients have received the therapy through the collaboration of the University Hospital Heidelberg and the JRC. Many of the patients are expected to relapse after a certain time. However, the scientists have seen several long-lasting full responses, among which one case surpassing two years without relapse. The therapeutic responses observed in the majority of patients to date indicate that TAT with 225Actinium-PSMA-617 has the potential to change the future treatment of metastatic prostate cancer.

To read more please visit: https://ec.europa.eu/jrc/en/news/prostate-cancer-alpha-therapy-shows-impressive-results

Source: European Commission